亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

医学 来那度胺 伊布替尼 化学免疫疗法 弥漫性大B细胞淋巴瘤 内科学 肿瘤科 美罗华 化疗方案 无进展生存期 化疗 淋巴瘤 多发性骨髓瘤 白血病 慢性淋巴细胞白血病
作者
Jason R. Westin,Raphaël Steiner,Dai Chihara,Sairah Ahmed,Preetesh Jain,Luis Malpica,Swami P. Iyer,Luis Fayad,Ranjit Nair,Loretta J. Nastoupil,Sattva S. Neelapu,Jared Henderson,Maria Alma Rodriguez,Fredrick B. Hagemeister,Francisco Vega,Brendan Pulsifer,J. Tom,Isak Durmic,Gita Masand,Lei Feng,Michael R. Green,Christopher R. Flowers,Paolo Strati
出处
期刊:Blood [American Society of Hematology]
卷期号:142 (Supplement 1): 856-856
标识
DOI:10.1182/blood-2023-180381
摘要

Background: Despite recent advances, first-line (1L) chemoimmunotherapy (CIT) for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades.In the Smart Start trial, we established the feasibility of targeted chemotherapy-free 1L therapy with rituximab (R), lenalidomide (L), and ibrutinib, prior to chemotherapy in patients with newly diagnosed DLBCL with an overall response rate (ORR) and complete response rate (CRR) of 86% and 36%, respectively, prior to chemotherapy, and a 2 year progression free survival rate of 91.3% following 6 cycles of standard CIT (Westin et al, JCO 2023, PMID: 35952327). One patient withdrew from the study after achieving CR and prior to receiving CIT and remains in remission without further therapy at >4 years. BTK inhibitors like acalabrutinib (A) and the immunomodulatory agent L result in synthetic lethality in non-GCB DLBCL models. Both the CD20 antibody R and CD19 antibody tafasitamab (T) demonstrate clinical activity when combined with L in patients with DLBCL. L, T, R, and A are immunomodulatory, driving an anti-tumor immune response. Based upon these data, we are conducting the Smart Stop trial (NCT04978584) to evaluate if the number of CIT cycles can be reduced or omitted after response to targeted therapy, and now report the preplanned interim results from cohort 1. Methods: Eligibility criteria include patients who are 18y+ with previously untreated DLBCL (initially the Hans algorithm was used to select non-GCB DLBCL, but this criteria was removed this criteria) with adequate organ and bone marrow function. Patients with known CNS involvement of lymphoma, recent thrombosis, or inability to tolerate prophylactic anticoagulation are ineligible. Patients receive lenalidomide 25mg on days (d) 1-10, tafasitamab 12mg/kg IV d1, 8, and 15, rituximab 375mg/m2 IV d1, and acalabrutinib 100mg PO twice/d in a 21 day cycle. All patients receive LTRA for 4 cycles, followed by PET/CT scan (CR defined as a 5PS of 1, 2, or 3). In cohort 1, patients receive an additional 6 cycles of LTRA combined with a response adapted number of cycles of CHOP therapy. After 4 cycles of LTRA, patients with CR receive 2 cycles of CHOP, and all other patients receive 6 cycles of CHOP. In the upcoming cohort 2, patients with CR after 4 cycles of LTRA are planned to receive no cycles of CHOP. The primary objectives are to determine the 1A: ORR after 4 cycles of uLTRA and 1B: CRR at of LTRA +/-CHOP at the end of therapy. Results: Cohort 1 enrolled 30 patients from May 2022 - July 2023, with all patients expected to be evaluable for 1A endpoint and 22 patients (73%) evaluable for endpoint 1B by the ASH meeting. The median age was 61 years (range: 32-85), 30% were >= 70 years, and 50% were female. 67% of patients have poor risk R-IPI, 77% had advanced stage, and 83% had an elevated LDH. 83% had the non-GCB subtype and 17% had the GCB subtype of DLBCL. After 4 cycles of LTRA, the ORR is 100% and the CRR is 64% (endpoint 1A, n = 14/22 evaluable at abstract submission, figure 1 schema and swimmer plot). After an additional 2 cycles of LTRA-CHOP, the ORR is 100% and the CRR is 95% (n = 18/19 evaluable at abstract submission). At end of all therapy, the CRR is 100% (endpoint 1B, n = 12 evaluable at abstract submission), including 7 patients who received LTRA for 10 cycles and CHOP for 2 cycles (early CR) and 5 patients who received LTRA for 10 cycles and CHOP for 6 cycles. To date, no patient has progressive lymphoma, including the first 6 patients who have 3 and 6 month follow up scans. 47% of patients experienced rash (13% grade 3), and 40% of patients required a dose reduction of lenalidomide. Conclusions: The Smart Stop trial demonstrates that combination of lenalidomide, tafasitamab, rituximab, and acalabrutinib is highly effective as an initial chemotherapy-free combination in patients with newly diagnosed DLBCL, and may allow for a response adapted reduction in chemotherapy. Response and time to event data will be updated for presentation at the meeting. We will soon open cohort 2 which will enroll an additional 30 patients where those with early CR after 4 cycles of LTRA will receive no cycles of CHOP.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天快乐应助高小羊采纳,获得10
1分钟前
1分钟前
高小羊发布了新的文献求助10
1分钟前
打打应助郜南烟采纳,获得10
1分钟前
高小羊完成签到,获得积分10
1分钟前
LouieHuang完成签到,获得积分20
2分钟前
2分钟前
郜南烟发布了新的文献求助10
2分钟前
wanci应助郜南烟采纳,获得10
2分钟前
上官若男应助zhangyimg采纳,获得10
2分钟前
2分钟前
Lorin完成签到 ,获得积分10
2分钟前
3分钟前
zhangyimg发布了新的文献求助10
3分钟前
科目三应助zhangyimg采纳,获得10
3分钟前
gszy1975完成签到,获得积分10
4分钟前
圆圆的波仔发布了新的文献求助100
4分钟前
JamesPei应助科研通管家采纳,获得10
4分钟前
郗妫完成签到,获得积分10
5分钟前
6分钟前
郜南烟发布了新的文献求助10
6分钟前
Venus完成签到 ,获得积分10
7分钟前
在水一方应助chenyuns采纳,获得30
7分钟前
JACk完成签到 ,获得积分10
8分钟前
8分钟前
chenyuns发布了新的文献求助30
8分钟前
爱静静应助李伟采纳,获得10
8分钟前
8分钟前
zhangyimg发布了新的文献求助10
8分钟前
9分钟前
郜南烟发布了新的文献求助10
9分钟前
斯文败类应助郜南烟采纳,获得10
9分钟前
思源应助chenyuns采纳,获得20
9分钟前
Akim应助chenyuns采纳,获得20
9分钟前
领导范儿应助圆圆的波仔采纳,获得10
10分钟前
11分钟前
11分钟前
李爱国应助怕孤单的灵寒采纳,获得10
11分钟前
圆圆的波仔完成签到,获得积分10
11分钟前
11分钟前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
叶剑英与华南分局档案史料 500
Foreign Policy of the French Second Empire: A Bibliography 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3146771
求助须知:如何正确求助?哪些是违规求助? 2798063
关于积分的说明 7826621
捐赠科研通 2454573
什么是DOI,文献DOI怎么找? 1306394
科研通“疑难数据库(出版商)”最低求助积分说明 627708
版权声明 601527